MediWound (NASDAQ:MDWD) Stock Price Passes Below 200-Day Moving Average – Time to Sell?

Shares of MediWound Ltd. (NASDAQ:MDWD) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $16.82 and traded as low as $14.70. MediWound shares last traded at $14.82, with a volume of 64,553 shares.

Analyst Ratings Changes

MDWD has been the subject of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a research report on Tuesday, April 21st. HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price on shares of MediWound in a research report on Thursday, May 28th. Wall Street Zen raised shares of MediWound from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 30th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $32.00 price target (down from $33.00) on shares of MediWound in a report on Wednesday, May 27th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $34.00.

MediWound Price Performance

The firm has a fifty day moving average of $15.44 and a two-hundred day moving average of $16.82. The stock has a market capitalization of $190.44 million, a P/E ratio of -6.56 and a beta of 0.14.

MediWound (NASDAQ:MDWD) last posted its earnings results on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.42. MediWound had a negative net margin of 180.30% and a negative return on equity of 67.22%. The business had revenue of $1.48 million for the quarter, compared to the consensus estimate of $3.37 million. During the same quarter last year, the firm posted ($0.07) EPS. As a group, sell-side analysts forecast that MediWound Ltd. will post -2.31 EPS for the current fiscal year.

Insider Activity

In other MediWound news, Director David Morton Fox acquired 3,537 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were purchased at an average cost of $14.11 per share, for a total transaction of $49,907.07. Following the completion of the purchase, the director owned 22,283 shares in the company, valued at approximately $314,413.13. This trade represents a 18.87% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 9.20% of the company’s stock.

Institutional Trading of MediWound

A number of hedge funds have recently bought and sold shares of the stock. Quarry LP bought a new position in MediWound in the fourth quarter worth about $26,000. BNP Paribas Financial Markets boosted its holdings in shares of MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 723 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 649 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 999 shares during the last quarter. Finally, MetLife Investment Management LLC bought a new position in shares of MediWound during the 4th quarter worth approximately $109,000. Hedge funds and other institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.